NCT04988555 2026-03-24
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
Phase 1/2 Recruiting
Sumitomo Pharma America, Inc.
University of Miami
Mayo Clinic
CellCentric Ltd.
Universitätsklinikum Hamburg-Eppendorf
Oncotherapeutics